Important Short Interest Filing: What’s Ahead for Pronai Therapeutics Incorporated (NASDAQ:DNAI) After More Shorted Shares?

December 1, 2016 - By Clifton Ray   ·   0 Comments

Important Short Interest Filing: What’s Ahead for Pronai Therapeutics Incorporated (NASDAQ:DNAI) After More Shorted Shares?

The stock of Pronai Therapeutics Incorporated (NASDAQ:DNAI) registered an increase of 26.63% in short interest. DNAI’s total short interest was 1.42M shares in December as published by FINRA. Its up 26.63% from 1.12 million shares, reported previously. With 564,900 shares average volume, it will take short sellers 3 days to cover their DNAI’s short positions. The short interest to Pronai Therapeutics Incorporated’s float is 6.16%. The stock last traded at $1.33 per share. It is down 76.99% since April 28, 2016 and is downtrending. It has underperformed by 82.92% the S&P500.

ProNAi Therapeutics, Inc. is a clinical-stage oncology company. The company has a market cap of $38.40 million. The Firm is engaged in business of researching, developing and commercializing therapies for the treatment of patients with cancer and hematological diseases based on its deoxyribonucleic acid interference technology platform. It currently has negative earnings. The Company’s lead product candidate includes PNT2258, which targets cancers that overexpress B-cell lymphoma 2 (BCL2), an oncogene known to be dysregulated in various types of cancer.

ProNAi Therapeutics Inc (NASDAQ:DNAI) Ratings Coverage

Out of 5 analysts covering ProNAi Therapeutics (NASDAQ:DNAI), 3 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 60% are positive. ProNAi Therapeutics has been the topic of 9 analyst reports since August 10, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating by SunTrust given on Wednesday, September 9. Jefferies downgraded the shares of DNAI in a report on Monday, June 6 to “Hold” rating. The rating was downgraded by Suntrust Robinson to “Neutral” on Monday, June 6. Wedbush initiated ProNAi Therapeutics Inc (NASDAQ:DNAI) on Monday, August 10 with “Outperform” rating. The firm earned “Buy” rating on Wednesday, September 9 by Suntrust Robinson. The firm has “Buy” rating by Jefferies given on Wednesday, September 9. The firm has “Buy” rating given on Monday, August 10 by Bank of America. Jefferies initiated ProNAi Therapeutics Inc (NASDAQ:DNAI) on Monday, August 10 with “Buy” rating.

DNAI Company Profile

ProNAi Therapeutics, Inc., incorporated on May 8, 2003, is a clinical-stage oncology company. The Firm is engaged in business of researching, developing and commercializing therapies for the treatment of patients with cancer and hematological diseases based on its deoxyribonucleic acid interference (DNAi) technology platform. The Company’s lead product candidate includes PNT2258, which targets cancers that overexpress B-cell lymphoma 2 (BCL2), an oncogene known to be dysregulated in various types of cancer. The Company’s PNT2258 is a formulation of its single-stranded 24-base DNAi oligonucleotide, known as PNT100, encapsulated in the SMARTICLES Lipid Nanoparticle (LNP). The Company’s PNT2258 consists of over two components, including PNT100 DNAi Oligonucleotide and LNP Delivery Technology.

More notable recent ProNAi Therapeutics Inc (NASDAQ:DNAI) news were published by: Marketwatch.com which released: “/quotes/zigman/3870025/realtime” on June 14, 2015, also Prnewswire.com with their article: “SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of …” published on November 23, 2016, Marketwatch.com published: “ProNAi Therapeutics’ stock plunges toward record low after disappointing trial …” on June 06, 2016. More interesting news about ProNAi Therapeutics Inc (NASDAQ:DNAI) were released by: Finance.Yahoo.com and their article: “Robbins Arroyo LLP: ProNAi Therapeutics, Inc. (DNAI) Misled Shareholders …” published on November 15, 2016 as well as Quotes.Wsj.com‘s news article titled: “News ProNAi Therapeutics Inc.DNAI” with publication date: July 10, 2015.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Clifton Ray


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>